# CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

> **NCT04578600** · PHASE1 · COMPLETED · sponsor: **Joseph Tuscano** · enrollment: 8 (actual)

## Conditions studied

- Indolent B-Cell Non-Hodgkin Lymphoma
- Recurrent B-Cell Non-Hodgkin Lymphoma
- Recurrent Chronic Lymphocytic Leukemia
- Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma
- Recurrent Follicular Lymphoma
- Recurrent Hairy Cell Leukemia
- Recurrent Lymphoplasmacytic Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma
- Refractory B-Cell Non-Hodgkin Lymphoma
- Refractory Chronic Lymphocytic Leukemia
- Refractory Mucosa-Associated Lymphoid Tissue Lymphoma
- Refractory Follicular Lymphoma
- Refractory Hairy Cell Leukemia
- Refractory Lymphoplasmacytic Lymphoma
- Refractory Mantle Cell Lymphoma
- Refractory Marginal Zone Lymphoma
- Recurrent Small Lymphocytic Lymphoma
- Refractory Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Lenalidomide
- **BIOLOGICAL:** Obinutuzumab
- **DRUG:** Oral Azacitidine

## Key facts

- **NCT ID:** NCT04578600
- **Lead sponsor:** Joseph Tuscano
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-23
- **Primary completion:** 2023-12-12
- **Final completion:** 2025-02-21
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2025-04-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04578600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04578600, "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04578600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*